Clinical trials: Adolescent Immunizations
Tick Born Encephalitis
Safety and Long-term Evaluation (up to 5 Years) of First Booster Immunization With Novartis' TBE Vaccine for Adults in Adolescents and Adults
evaluate safety and immunogenicity of first TBE booster and long-term immunogenicity up to 5 years after first TBE booster
- Trial name
- NCT00387634
- Testing
- TBE vaccine for adults
- Where
- Czechia
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningococcal Immunisation (Healthy Volunteers)
Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age
Primary Objective: To demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W)…
- Trial name
- NCT04368429
- Testing
- Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate Vaccine), Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
- Where
- 4 sites in Japan
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Sanofi
Vaccine, Human Papiloma Virus Vaccine
State Immunization Information Systems to Improve HPV Vaccination Rates
The overarching goal of this study is to evaluate the effectiveness, cost-effectiveness and sustainability of utilizing statewide Immunization Information Systems (IIS) to conduct centralized reminder/recall (R/R) to improve…
- Conditions
- Vaccine, Human Papiloma Virus Vaccine, HPV Vaccine, Immunization
- Trial name
- NCT02993965
- Testing
- Vaccine Reminder/Recall
- Where
- United States
- Volunteers
- 77,716 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Human Papilloma Virus
Increasing HPV Immunization Rates: The Rural Adolescent Vaccine Enterprise
The goal of this study is to engage rural primary care clinics and community organizations to test interventions designed to increase HPV vaccinations in both male and female patients aged 9-26 years.
- Trial name
- RAVE (NCT03604393)
- Testing
- Practice facilitation
- Where
- United States
- Volunteers
- 22,000 people
- Sponsor
- Oregon Health and Science University
Human Papillomavirus (HPV) Vaccine, Human Papillomavirus (HPV) Vaccines
Strengthening HPV Vaccination and Adolescent Health Research Program in Nigeria (SHARP)
The goal of this clinical trial is to learn whether adding adolescent health services to routine government health programs can increase Human Papillomavirus (HPV) vaccination coverage among 9-year-old girls and improve use of…
- Conditions
- Human Papillomavirus (HPV) Vaccine, Human Papillomavirus (HPV) Vaccines, Human Papillomavirus (HPV) Infections, Adolescent Health Services
- Trial name
- SHARP (NCT07200414)
- Testing
- Integrated Adolescent Health Package, Routine Government Health Services
- Where
- Nigeria
- Volunteers
- 12,654 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Papillomavirus Infections, Uterine Cervical Neoplasms
Improving HPV Vaccination Coverage Among Adolescent Girls in Mali and Côte d'Ivoire Through Community Health Worker Follow-up
The goal of this trial is to learn if a community health worker (CHW) follow-up program can improve HPV vaccination coverage among adolescent girls in Mali and Côte d'Ivoire.
- Trial name
- NCT07807202
- Testing
- HPV vaccination pro-active community-based follow-up model, Standard community mobilization
- Where
- 2 sites in Côte d’Ivoire, Mali
- Volunteers
- 17,188 people
- Sponsor
- Arsène Brunelle Sandie
Papillomavirus Vaccines, Adolescent Health Services
AFIX to Improve HPV Vaccination
The University of North Carolina will test the effectiveness of the Centers for Disease Control and Prevention's AFIX model for increasing HPV vaccination coverage among adolescents.
- Trial name
- AFIX (NCT02370459)
- Testing
- AFIX in-person consultation, AFIX webinar consultation
- Where
- 4 sites in United States
- Volunteers
- 223 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Influenza Immunization
Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.
The purpose of this study was to demonstrate the non-inferiority (NI) of the HAI immune response of RIV4 in participants aged 9 to 17 years vs participants aged 18 to 49 years and to describe the immunogenicity and safety profile…
- Trial name
- NCT05513053
- Testing
- Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH
- Where
- 35 sites in United States, Czechia and 2 more
- Volunteers
- 1,308 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company